옵션 체인은 다양한 행사가격과 만기일에 대한 Simulations Plus의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Simulations Plus에 대한 시장 심리를 평가합니다..

Simulations Plus (NASDAQ:SLP) 주식, 옵션 체인

Simulations Plus

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Silver,Spring,,Md,,Usa,-,June,25,,2022:,The,Fda

Biotech

Government

News

Regulations

Health Care

After-Hours Center

Movers

ABSI

CERT

RXRX

SDGR

미국 식품의약국(FDA)이 동물실험 의무 조항을 단계적으로 폐지할 계획을 발표했다. 이에 목요일(10일) 장 마감 후 헬스케어 기술 분야의 여러 주식이 상승세를 보이고 있다.

美FDA, 동물실험 의무 조항 단계적 폐지 발표...헬스케어 기술 주식 급등

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

Pre-Market Outlook

Markets

Trading Ideas

NMTC

SGMO

금요일(4일) 아침 미국 지수 선물이 하락세를 보이는 가운데, 오늘 투자자의 관심을 끌 수 있는 주식은 다음과 같다. 금요일 주목해야 할 주식: 아메리칸 셰어드, 게스, 뉴로원 메디컬, 시뮬레이션스 및 상가모 테라퓨틱스

금요일 주목해야 할 주식: 아메리칸 셰어드, 게스, 뉴로원 메디컬, 시뮬레이션스 및 상가모 테라퓨틱스

Small Cap

LEVI

주식선물이 이번 목요일 아침 미국에서 상승하면서, 오늘 투자자들의 주목을 끌 수 있는 몇 가지 주식은 다음과 같습니다.

월스트리트는 Conagra Brands, Inc.(NYSE:CAG)의 오프닝벨 전에 1주당 65센트의 분기 실적과 301억달러의 매출을 발표할 것으로 예상하고 있습니다. 이는벤징가 프로의 데이터에 따른 것입니다. Conagra 주식은 매출 후 시간에 1.2% 상승하여

리바이스, 콘아그라 브랜즈와 목요일로 향하는 3종목의 주식

Simulations Plus Inc

Smooth Love Potion - United States Dollar

SIMPLEX HLDGS INC by SIMPLEX HLDGS INC.

Simulations Plus is reaffirming the preliminary revenue for its third fiscal quarter and full year 2025 revenue guidance which was previously provided on June 11, 2025.
<ul>
<li>The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million</li>
<li>Full year fiscal 2025 revenue is expected to range between $76 million and $80 million</li>
</ul>

Guidance

Simulations Plus Reaffirms Q3 FY2025 Revenue of $19M–$20M And Full-Year Revenue Of $76M–$80M

To be released on July 14, 2025, with conference call at 5 p.m. ET
Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has rescheduled the release of its financial results and conference call for the third fiscal quarter ended May 31, 2025, which had previously been scheduled for July 2, 2025.
The Company currently expects to issue its third quarter results after market close and hold its conference call on Monday, July 14, 2025, at 5:00 p.m. Eastern Time. Since transitioning from a large accelerated filer to a non-accelerated filer, the Company is using the all of the time allowed by regulation before releasing its third quarter financial results.

Simulations Plus Announces Rescheduling Of Q3 2025 Earnings Release From July 2, 2025 To July 14, 2025

JMP Securities analyst Constantine Davides reiterates Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) from Market Perform to Market Perform.

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Perform on Simulations Plusto Market Perform

Craig-Hallum analyst Matt Hewitt maintains Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Buy and lowers the price target from $45 to $36.

Price Target

Craig-Hallum Maintains Buy on Simulations Plus, Lowers Price Target to $36

Simulations Plus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) stock tanked after the company lowered its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45893492/simulations-plus-announces-preliminary-third-quarter-fiscal-2025-revenue" rel="noreferrer noopener">fiscal 2025 sales outlook</a>.
The company expects third-quarter sales of $19 million-$20 million, much below the consensus of $22.78 million.
On Wednesday, the company cut its 2025 sales forecast to $76 million—$80 million versus a consensus of $90.26 million, down from prior guidance <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44635451/simulations-plus-reports-second-quarter-fiscal-2025-financial-results" rel="noreferrer noopener">of $90 million—$93 million</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44764201/whats-going-on-with-charles-river-certara-simulations-plus-stocks-on-friday" rel="noreferrer noopener">What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?</a>
"Market uncertainties surrounding future funding, drug pricing and potential tariffs are creating significant headwinds for both our pharmaceutical and biotech clients, resulting in budget reductions, project cancellations, and delays that are more pronounced than what we have experienced over the past two years," said Shawn O'Connor, CEO of Simulations Plus.
"While our software segment has remained relatively resilient, given its role as critical infrastructure in drug development programs, demand for services has proven more sensitive to market volatility and is coming in below our expectations."
Earlier in June, the company restructured its operations to reduce its workforce and implemented focused cost reductions to enhance operational efficiency and <a target="_blank" href="https://www.benzinga.com/secfilings/25/06/45718737/simulations-plus-inc-general-corporate-statement-form8" rel="noreferrer noopener">reduce operating expenses</a>.
The workforce reduction will decrease the overall headcount by approximately 23 employees, representing approximately 10% of full-time employees as of the Effective Date.
The company estimates that it will incur approximately $0.7 million in charges for the restructuring.
William Blair writes, "We are surprised Simulations Plus decided not to include yesterday's update in its restructuring announcement last week (which has already caused the stock to fall by almost 17%).
"While we had assumed a guidance cut was coming on the back of last week's release, the size of the downward revision was significantly greater than we had expected. We are admittedly left with more questions than answers at this point, particularly with respect to the impact on margins for the remainder of this year and the company's outlook for fiscal 2026," analyst Max Smock wrote on Thursday.
William Blair maintains the Outperform <a target="_blank" href="https://www.benzinga.com/quote/SLP/analyst-ratings" rel="noreferrer noopener">rating on Simulations Plus</a>.
Price Action: SLP stock is down 23.2% at $20.30&nbsp;at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45261078/charles-river-laboratories-q1-earnings-beat-consensus-stock-trades-higher-on-signs-of-demand-" target="_blank" rel="noreferrer noopener">Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization</a></li>
</ul>
Photo by jittawit21 via Shutterstock

Analyst Color

General

Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares moved upwards by 270.6% to $0.03 during Thursday's regular session. The company's market cap stands at $13.9 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares moved upwards by 51.3% to $16.81. The market value of their outstanding shares is at $437.3 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares moved upwards by 42.76% to $2.07. The company's market cap stands at $67.2 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock moved upwards by 34.49% to $3.08. The company's market cap stands at $2.2 million. </li>
<li>Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) shares increased by 30.69% to $8.09. The company's market cap stands at $260.4 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares moved upwards by 30.06% to $1.04. The company's market cap stands at $5.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock fell 45.1% to $0.32 during Thursday's regular session. The market value of their outstanding shares is at $5.8 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock declined by 44.14% to $0.62. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares declined by 33.35% to $0.15. The company's market cap stands at $1.6 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) stock declined by 33.17% to $1.33. The company's market cap stands at $44.0 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares declined by 27.83% to $0.43. The company's market cap stands at $4.7 million. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares decreased by 22.28% to $20.55. The market value of their outstanding shares is at $413.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HCTI

HSDT

INTS

JUNS

KLTO

LIMN

PLRZ

RSLS

SGMT

SHPH

VTAK

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares rose 36.0% to $0.53 during Wednesday's after-market session. The company's market cap stands at $18.7 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares rose 30.43% to $0.01. The market value of their outstanding shares is at $4.9 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock increased by 17.01% to $13.0. The market value of their outstanding shares is at $338.1 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) shares rose 8.53% to $7.5. The market value of their outstanding shares is at $174.7 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares moved upwards by 7.27% to $1.77. The market value of their outstanding shares is at $35.6 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) shares moved upwards by 6.79% to $5.97. The company's market cap stands at $32.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock declined by 53.4% to $0.52 during Wednesday's after-market session. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares declined by 27.48% to $0.42. The company's market cap stands at $7.7 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares fell 24.13% to $1.51. The market value of their outstanding shares is at $49.9 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 17.85% to $0.49. The market value of their outstanding shares is at $5.4 million. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares declined by 13.02% to $23.0. The market value of their outstanding shares is at $462.5 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 10.28% to $0.33. The market value of their outstanding shares is at $1.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAMP

DERM

NUWE

SCLX

12 Health Care Stocks Moving In Wednesday's After-Market Session

Simulations Plus Expects Q3 Revenue Between $19M And $20M; Now Sees FY25 Revenue Of $76M - $80M

Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the industry-leading software and consulting service expertise to successfully implement the FDA roadmap.

Simulations Plus Supports FDA's Plan to Reduce Animal Testing with New Approach Methodologies

Keybanc analyst Scott Schoenhaus maintains Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight and raises the price target from $32 to $40.

Keybanc Maintains Overweight on Simulations Plus, Raises Price Target to $40

WIIM

ABCL

Shares of healthcare technology stocks are trading higher. Some stocks in the sector rose after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 300 points on Friday.
The Dow traded up 0.78% to 39,903.35 while the NASDAQ gained 1.14% to 16,573.81. The S&amp;P 500 also rose, gaining, 0.92% to 5,316.66.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44757629/top-2-consumer-stocks-that-may-collapse-this-quarter">Top 2 Consumer Stocks That May Collapse This Quarter</a>
Leading and Lagging Sectors Information technology shares surged by 1.2% on Friday.
In trading on Friday, consumer discretionary shares fell by 1%.
Top Headline
The University of Michigan consumer sentiment dipped to 50.8 in April, recording the weakest level since June, compared to 57 in March.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Mixed Martial Arts Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) shares shot up 77% to $1.4101 after the company secured $2 million non-dilutive financing.</li>
<li>Shares of MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>)got a boost, surging 89% to $2.4099. On Thursday, the company entered into a strategic term sheet with Hazel Partners, Virage Capital and affiliates to execute a series of restructuring initiatives.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares were also up, gaining 21% to $31.18. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares dropped 52% to $2.39 after the company announced exercise of warrants for $1.8 million gross proceeds.</li>
<li>Shares of Steel Partners Holdings L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPLP#NYSE">SPLP</a>) were down 15% to $31.15 as the company reported voluntary NYSE delisting and SEC deregistration.</li>
<li>Frontier Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) was down, falling 13% to $3.1050. Evercore ISI Group analyst Duane Pfennigwerth maintained Frontier Group with an In-Line rating and lowered the price target from $7 to $5.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $60.50 while gold traded up 2.5% at $3,257.80.
Silver traded up 4.3% to $32.08 on Friday, while copper rose 4.8% to $4.5460.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.10%, Germany's DAX 40 fell 0.92% and France's CAC 40 slipped 0.30%. Spain's IBEX 35 Index fell 0.18%, while London's FTSE 100 rose 0.64%.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 dipping 2.96%, China's Shanghai Composite gaining 0.45%, Hong Kong's Gang Seng index rising 1.13% and India's BSE Sensex jumping 1.77%.
Economics
<ul>
<li>U.S. producer prices fell 0.4% month-over-month in March compared to a 0.1% gain in the previous month.</li>
<li>The University of Michigan consumer sentiment dipped to 50.8 in April, recording the weakest level since June, compared to 57 in March.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44758556/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Eurozone

Commodities

Intraday Update

LUCY

MSPR

SPLP

ULCC

Gold Gains Over 2%; US Consumer Sentiment Dips In April

The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">traditional animal testing</a>.
The agency aims to adopt human-relevant and technologically advanced testing methods to improve safety evaluations, reduce research costs and accelerate drug development timelines.
The FDA&#8217;s new approach, <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs" rel="noreferrer noopener">outlined</a> in a roadmap released on Thursday, encourages drug developers to integrate New Approach Methodologies (NAMs), including AI-driven simulations and laboratory-based human models.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44761003/sony-nintendo-hike-console-prices-as-us-tariffs-bite-microsoft-may-dodge-the-hit" rel="noreferrer noopener">Sony, Nintendo Hike Console Prices As US Tariffs Bite, Microsoft May Dodge The Hit</a>
These alternatives are expected to provide more accurate predictions of human responses and toxicities, which can be difficult to detect through animal testing alone.
One key strategy promoted in the roadmap is the use of advanced computer modeling.
AI-based simulations can mimic how monoclonal antibodies travel through the human body and predict potential side effects based on the drug&#8217;s structure. The FDA believes this could significantly reduce the reliance on animals in preclinical studies.
In addition, the agency is supporting the use of lab-grown human organoids and organ-on-a-chip technologies.
These systems replicate the function of human organs like the liver and heart, offering a more precise picture of how a drug might behave in the human body.
Such human-based models have the potential to detect adverse effects that may not surface in animal studies.
To incentivize the adoption of these methods, the FDA plans to update regulatory guidelines and offer streamlined reviews for applications supported by NAMs data.
This could shorten development timelines and lower the cost of bringing monoclonal antibody therapies to market.
The agency will also begin using real-world safety data from countries with comparable regulatory standards, particularly for drugs already tested in humans abroad.
This marks another step toward reducing redundant animal testing while maintaining rigorous safety standards.
The FDA is working to validate and expand these alternative methods in collaboration with federal agencies such as the National Institutes of Health and the Department of Veterans Affairs.
A public workshop is scheduled later this year to gather feedback from stakeholders on the roadmap&#8217;s rollout.
Over the next year, the FDA will pilot a program allowing select developers to rely primarily on non-animal testing methods for monoclonal antibody development.
William Blair writes that even though these changes will be rolled out gradually over time, drug developers will still want to do at least some animal testing. This may be a major overhang for Charles River Laboratories International, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), which generates roughly 20% of its revenue from testing drugs in non-human primates. The stock plunged over 20% on Thursday.
Analyst Max Smock adds that the move can be potentially favorable to Certara Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) and Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), both of which have preclinical models that can be used in place of or in conjunction with animal-based testing.
CRL, CERT, SLP Price Actions: Charles River stock is down 1.84% at $96.68, Certara stock is up 13.5% at $11.96 and Simulations Plus stock is up 22.80% at $31.61 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertainties" target="_blank" rel="noreferrer noopener">Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties</a></li>
</ul>
Photo: Shutterstock

Large Cap

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

U.S. stocks were lower, with the Dow Jones index dipping over 250 points on Friday.
Shares of Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) rose sharply during Thursday's session following better-than-<a href="https://www.benzinga.com/news/earnings/25/04/44761872/fastenal-beats-revenue-estimates-in-q1-but-margins-narrow-as-costs-rise">expected first-quarter sales.</a>
Fastenal on Friday reported first-quarter 2025 revenue of $1.959 billion, a 3.4% year-over-year increase and slightly above the $1.95 billion consensus estimate. Adjusting for one less selling day and the absence of Good Friday in March, net daily sales grew 5.0%.
Fastenal shares jumped 3.3% to $78.31 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>CeriBell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) shares jumped 30.3% to $14.52.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) gained 28% to $5.77.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) rose 19.3% to $30.72. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 16.2% to $28.26.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) rose 15.2% to $2.8300.</li>
<li>Schrödinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) gained 13.6% to $21.84.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 13.55% to $32.07.</li>
<li>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) rose 12.6% to $11.84. Baird analyst Joe Vruwink maintained Certara with a Neutral and raised the price target from $9 to $13.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) gained 12% to $8.18.</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) gained 10.6% to $230.00.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) gained 10.6% to $28.11.</li>
<li>AngloGold Ashanti plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) rose 8.5% to $42.15.</li>
<li>Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) jumped 7.6% to $9.72.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44759875/mckesson-to-rally-more-than-11-here-are-10-top-analyst-forecasts-for-friday">McKesson To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Friday</a> </li>
</ul>
Photo via Shutterstock

AMRN

CBLL

FAST

NMAX

ZLAB

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday

<h3>Gainers</h3>
<ul>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares increased by 124.2% to $2.87 during Friday's pre-market session. The company's market cap stands at $6.0 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 31.69% to $0.02. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares moved upwards by 22.17% to $31.45. The company's market cap stands at $632.4 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock rose 20.43% to $7.77. The company's market cap stands at $5.8 million. </li>
<li>Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) stock moved upwards by 18.36% to $12.44. The market value of their outstanding shares is at $2.0 billion. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) stock moved upwards by 17.74% to $2.19. The market value of their outstanding shares is at $162.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) shares declined by 38.0% to $1.5 during Friday's pre-market session. The company's market cap stands at $117.4 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 35.26% to $0.18. The market value of their outstanding shares is at $1.1 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock decreased by 31.64% to $0.29. The company's market cap stands at $7.5 million. </li>
<li>KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) shares fell 29.39% to $1.61. The market value of their outstanding shares is at $74.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) stock declined by 24.78% to $1.64. The market value of their outstanding shares is at $2.9 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock declined by 23.08% to $8.0. The market value of their outstanding shares is at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CATX

KRMD

MESO

NAOV

ONVO

PHLT

STSS

YCBD

12 Health Care Stocks Moving In Friday's Pre-Market Session

JPM: 4% &#x7C; <a href="https://www.benzinga.com//node/44757891">JPMorgan Chase shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.</a>
&nbsp;
SLP: 28% &#x7C; <a href="https://www.benzinga.com//node/44751076">Simulations Plus shares are trading higher. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</a>
&nbsp;
MSPR: 200% &#x7C; <a href="https://www.benzinga.com//node/44754787">MSP Recovery To Eliminate $1.2B In Liabilities Through Strategic Partnerships And Creation Of Independent Servicer</a>

Market-Moving News for April 11th

Shares of argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-injection in generalized myasthenia gravis and <a href="https://www.benzinga.com/quote/ARGX">chronic inflammatory demyelinating polyneuropathy.</a>
argenx shares jumped 5.1% to $573.88 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) rose 167% to $3.43 in pre-market trading as the company announced strategic term sheet providing prospective liquidity and restructuring of existing agreements to remove corporate guaranteed debt by over $1.2 billion as well as new agreements aimed at driving future growth.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) surged 73.6% to $0.0318 in pre-market trading after jumping 30% on Thursday.</li>
<li>Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) gained 26.5% to $0.3300 in pre-market after dipping 22% on Thursday.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) rose 26.4% to $0.8198 in pre-market trading. Actelis Networks recently announced it received a new order to modernize Orange County&#8217;s traffic infrastructure.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) rose 25.6% to $5.10 in pre-market trading. Venus Concept announced closing of $1.1 million registered direct offering of common stock priced at-the-market under Nasdaq rules.</li>
<li>DMC Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) gained 21.7% to $7.90 in pre-market trading.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) jumped 19.1% to $5.37 in pre-market trading.</li>
<li>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) surged 18.1% to $12.41 in pre-market trading after gaining 8% on Thursday.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) gained 13.7% to $29.23 in pre-market trading. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>AlTi Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) fell 57.3% to $1.20 in pre-market trading after declining around 6% on Thursday.</li>
<li>cbdMD, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#NYSE">YCBD</a>) shares tumbled 38.9% to $0.1701 in pre-market trading. CbdMD announced shareholder approval of automatic conversion of series a preferred stock and other results from annual meeting.</li>
<li>Nexa Resources S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) fell 32% to $4.01 in today's pre-market trading.</li>
<li>Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares fell 27.1% to $1.59 in pre-market trading.</li>
<li>Palatin Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>) fell 16.8% to $0.3510 in pre-market trading after the company announced it received a NYSE American notice of delisting.</li>
<li>Betterware de México, S.A.P.I. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) shares fell 24% to $8.21 in pre-market trading. Betterware de México will report its first quarter results after the U.S. market close on Thursday, April 24.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) shares dipped 22.3% to $2.20 in pre-market trading.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 14.9% to $2.35 in pre-market trading.</li>
<li>Costamare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) dipped 14.3% to $7.42 in pre-market trading after falling 5% on Thursday.</li>
<li>Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) declined 12.8% to $6.62 in pre-market trading after falling 5% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a> </li>
</ul>
Photo via Shutterstock

ALTI

ARGX

ASNS

BOOM

BWMX

CMRE

INNV

MAZE

NEXA

SLSR

VERO

Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket

Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to <a href="https://www.benzinga.com/fda-calendar">phase out animal testing requirements</a>.
What Happened: The FDA on Thursday announced plans to replace&nbsp;animal testing in the development of monoclonal antibody therapies and other drugs with human-relevant methods.
The FDA said it will phase out animal testing requirements in favor of AI-based computational models of toxicity and cell lines and organoid toxicity testing. Implementation is expected to begin immediately.
Health care tech and AI-powered biotech stocks making the biggest moves after the bell include Certara Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>), Schrodinger Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>), Simulations Plus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) and Absci Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>). All of the aforementioned names were up between 15% and 25% in Thursday&#8217;s after-hours session at the time of writing, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,&#8221; said Martin Makary, commissioner of the FDA.
&#8220;By leveraging AI-based computational modeling, human organ model-based lab testing and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&amp;D costs and drug prices.&#8221;
The policy changes will help improve the overall process by introducing advanced computer simulations, human-based lab models and regulatory incentives. The change is also expected to result in faster drug development. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44751312/wall-street-on-edge-bank-earnings-inflation-data-consumer-sentiment-set-stage-for-friday-fireworks">Wall Street Braces For High-Stakes Friday With Bank Earnings, Inflation Data, Consumer Sentiment In Focus</a></li>
</ul>
Photo: Tada Images/Shutterstock.

Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares moved upwards by 36.7% to $5.55 during Thursday's after-market session. The company's market cap stands at $3.6 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares moved upwards by 31.03% to $2.36. The company's market cap stands at $5.9 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares rose 30.27% to $2.84. The company's market cap stands at $5.1 million. </li>
<li>Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) stock moved upwards by 26.67% to $13.44. The company's market cap stands at $2.1 billion. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) stock moved upwards by 24.7% to $32.1. The company's market cap stands at $645.5 million. </li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock rose 20.61% to $5.44. The company's market cap stands at $2.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock fell 27.0% to $1.03 during Thursday's after-market session. The company's market cap stands at $34.7 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) shares fell 26.34% to $0.31. The company's market cap stands at $8.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock fell 13.77% to $4.29. The market value of their outstanding shares is at $10.5 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 13.29% to $0.38. The market value of their outstanding shares is at $2.0 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares declined by 10.86% to $5.75. The market value of their outstanding shares is at $4.3 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares declined by 9.72% to $0.25. The market value of their outstanding shares is at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CELZ

NIVF

NOTV

12 Health Care Stocks Moving In Thursday's After-Market Session

Simulations Plus shares are trading higher. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.

Press Releases

Simulations Plus to Participate in Upcoming Healthcare Investor Conferences

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum

Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date

Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

Simulations Plus Releases DILIsym® 11

Simulations Plus Releases ADMET Predictor® 13

Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue

Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum

Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call

Comments

Simulations Plus

Simulations Plus (SLP) 옵션

Simulations Plus (NASDAQ:SLP) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌